Search Result

Results for "

4 T1

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Acyltransferase (1) ADC Linker (1) Adenosine Receptor (1) Adrenergic Receptor (1) Akt (1) AMPK (1) Antibiotic (2) Apoptosis (22) Atg8/LC3 (1) ATTECs (2) AUTACs (1) Autophagy (4) Bacterial (3) Bcl-2 Family (4) Biochemical Assay Reagents (4) c-Myc (1) Carbonic Anhydrase (1) Casein Kinase (1) Caspase (2) CDK (24) CMV (1) COX (1) CXCR (1) Deubiquitinase (1) DNA Stain (1) DNA/RNA Synthesis (4) Drug Derivative (1) Drug-Linker Conjugates for ADC (2) DYRK (2) EGFR (2) Endogenous Metabolite (5) Epigenetic Reader Domain (4) ERK (2) FAK (1) Ferroptosis (1) FLT3 (1) Fungal (1) FXR (1) GCGR (1) GSK-3 (4) HDAC (2) Hedgehog (2) Hippo (MST) (1) Histone Acetyltransferase (1) Histone Methyltransferase (4) HIV (5) HSP (2) HSV (1) JAK (2) Liposome (1) Lipoxygenase (1) LPL Receptor (2) MAP4K (1) MEK (2) MELK (1) Microtubule/Tubulin (3) Mitochondrial Metabolism (1) MMP (1) Molecular Glues (1) mTOR (2) NAMPT (1) NOD-like Receptor (NLR) (2) Parasite (1) PD-1/PD-L1 (2) PDGFR (1) PDHK (1) Phosphatase (1) Phosphodiesterase (PDE) (3) Photosensitizer (3) PPAR (3) PROTACs (4) Protease Activated Receptor (PAR) (2) Reactive Oxygen Species (3) SARS-CoV (1) SHP2 (1) Small Interfering RNA (siRNA) (1) TAM Receptor (3) Taste Receptor (4) Tau Protein (1) TNF Receptor (1) Toll-like Receptor (TLR) (1) TrxR (1) VD/VDR (1) VEGFR (2) Virus Protease (1) YAP (1)
By Research Areas:	Cancer (85) Cardiovascular Disease (2) Infection (10) Inflammation/Immunology (21) Metabolic Disease (12) Neurological Disease (8)
Click Chemistry:	DBCO (1)
Oligonucleotides:	Aptamers (1) Cationic Lipids (1) Human Pre-designed siRNA Sets (1) siRNAs (1)

131

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P0229

Ribonuclease T1, Aspergillus oryzae Rnase T1	DNA/RNA Synthesis	Others
Ribonulease T1, Aspergillus oryzae (Rnase T1), is commonly used in biochemical research. Ribonuclease T1 is an endonuclease that can specifically degrade single stranded RNA. Ribonuclease T1 can form nucleoside 2 ', 3 '-cyclic phosphoric acid intermediates to cut the phosphodiester bond between 3' -guanosine residues and adjacent nucleoside 5 '-OH groups to produce 3' -GMP terminal oligonucleotides ^[1].

HY-111595

SAHA chloroalkane T1	Biochemical Assay Reagents	Cancer
SAHA chloroalkane T1 is a chloroalkane capture tag by tethering Vorinostat (SAHA) and a chloroalkane tag T1 ^[1].

HY-112624A

Dextran T1 (MW 1,000) Dextran 1; Dextran D1; Dextran T1(MW 800-1200)	Biochemical Assay Reagents	Others
Dextran T1 MW 1,000 (Dextran 1; Dextran D1; Dextran T1 MW 800-1200) is a polymer of anhydroglucose with the average molecular weight of 1000. Dextran T1 MW 1,000 exhibits good biodegradability and good biocompatibility, that is utilized in food, pharmaceutics, cosmetics, and research area ^[1].

HY-100950

ABC1183	GSK-3 CDK	Inflammation/Immunology Cancer
ABC1183 is an orally active selective dual GSK3 and CDK9 inhibitor. ABC1183 inhibits GSK3β, GSK3α and CDK9/cyclin T1 with the IC₅₀ values of 657 nM, 327 nM and 321 nM, respectively. ABC1183 has anti-inflammatory and anti-tumor activities ^[1].

HY-N11648

Ganoderic acid T1	Apoptosis Caspase	Inflammation/Immunology Cancer
Ganoderic acid T1 is a deacetylated derivative of Ganoderic acid T. Ganoderic acid T1 attenuates antioxidant defense system and induces apoptosis of cancer cells. Ganoderic acid T1 decreases mitochondrial membrane potential and activates caspase-9 and caspase-3, to trigger apoptosis. Ganoderic acid T1 also increases the generation of intracellular ROS to produce pro-oxidant activities and cytotoxicity ^[1].

HY-P0229A

Ribonuclease T1 (animal free) Rnase T1 (animal free)	DNA/RNA Synthesis	Others
Ribonuclease T1 (animal free) (Rnase T1 (animal free)) (EC 4.6.1.24) is an endonuclease that specifically degrades single-stranded RNA. Ribonuclease T1 forms a nucleoside 2′, 3′-cyclic phosphate intermediate to cleave the phosphodiester bond between the 3′-guanosine residue and the 5′-OH group of the adjacent nucleoside to produce a 3′-GMP-terminated oligonucleotide. This product does not contain ingredients of animal origin ^[1].

HY-156296

CDK9-Cyclin T1 PPI-IN-1	CDK Apoptosis	Cancer
CDK9-Cyclin T1 PPI-IN-1 (Compound B19) is a selective CDK9-Cyclin T1 protein-protein interaction (PPI) inhibitor. CDK9-Cyclin T1 PPI-IN-1 inhibits cell proliferation in TNBC MDA-MB-231 cells (IC₅₀: 0.044 μM), and induces apoptosis. CDK9-Cyclin T1 PPI-IN-1 inhibits CDK9 transcription activity, reduces the phosphorylation of RNA Pol II CTD ser2. CDK9-Cyclin T1 PPI-IN-1 inhibits tumor growth in a TNBC 4T1 mouse model ^[1].

HY-156084

LL-K9-3	CDK PROTACs Apoptosis c-Myc	Cancer
LL-K9-3 is a potent small-molecule degrader of CDK9-cyclin T1. LL-K9-3 has anti-proliferative and pro-apoptotic activities and suppresses downstream signaling of CDK9 and AR. Moreover, LL-K9-3 inhibits AR and Myc-driven oncogenic transcriptional programs ^[1].

HY-N14436

Pradimicin Tl	Antibiotic Fungal	Infection
Pradimicin T1 is an antibiotic. Pradimicin Tl has activity against filamentous fungi and yeast-like fungi ^[1].

HY-111356

IIIM-290	CDK	Cancer
IIIM-290 is a potent and oral CDK inhibitor with IC₅₀s of 90 and 94 nM for CDK2/A and CDK9/T1.

HY-137478

KB-0742 1 Publications Verification	CDK	Cancer
KB-0742 is a potent, selective and orally active CDK9 inhibitor with an IC₅₀ of 6 nM for CDK9/cyclin T1. KB-0742 is selective for CDK9/cyclin T1 with >50-fold selectivity over other CDK kinases. KB-0742 has potent anti-tumor activity ^[1].

HY-137478A

KB-0742 dihydrochloride 1 Publications Verification	CDK	Cancer
KB-0742 dihydrochloride is a potent, selective and orally active CDK9 inhibitor with an IC₅₀ of 6 nM for CDK9/cyclin T1. KB-0742 dihydrochloride is selective for CDK9/cyclin T1 with >50-fold selectivity over other CDK kinases. KB-0742 dihydrochloride has potent anti-tumor activity ^[1].

HY-162385

COX-2-IN-42	COX	Inflammation/Immunology
COX-2-IN-42 (Compound T1) is a COX-2 inhibitor, and protects zebrafish against PTZ-induced neuronal damage ^[1].

HY-130665

TL12-186 1 Publications Verification	PROTACs CDK	Cancer
TL12-186 is a Cereblon-dependent multi-kinase PROTAC degrader. Multi-kinases include CDK, BTK, FLT3, Aurora kinases, TEC, ULK, ITK, et al. TL12-186 inhibits CDK2/cyclin A (IC₅₀=73 nM) and CDK9/cyclin T1 (IC₅₀=55 nM) ^[1].

HY-145362

S1P1 agonist 4	LPL Receptor	Others
S1P1 agonist 4 has a better profile in both potency (EC₅₀ < 0.05 mg/kg) and predicted human half-life (t1/2 ∼ 5 days).

HY-118770

Nafetolol K 5407 free base	Adrenergic Receptor	Cardiovascular Disease
Nafetolol (K 5407), specifically effective on cardiac (β1)-adrenoceptors, is an orally active β blocking agent, with a t_1/2 of ~ 2 h in dogs ^[1].

HY-157334

DEG-77	Molecular Glues Casein Kinase	Cancer
DEG-77, a IKZF2 and *CK1α* targeted molecular glue, possesses suitable pharmacokinetic properties, solubility, and selectivity for in vivo studies (t_1/2=8h) ^[1].

HY-148571

TP0597850	MMP	Inflammation/Immunology Cancer
TP0597850 is a selective inhibitor of MMP2 (IC₅₀=0.22 nM). TP0597850 has a long MMP2 dissociation half-life (t_1/2=265 min) ^[1].

HY-16309

MB-07803	Phosphatase	Metabolic Disease
MB07803 is an orally available prodrug of a potent, noncompetitive inhibitor (MB07729) of fructose 1,6-bisphosphatase (FBPase), with EC₅₀ of 140 nM and *t_1/2* of 7.6±2.9 h.

HY-12843

Bohemine 1 Publications Verification	CDK ERK	Cancer
Bohemine is a purine analogue and is a synthetic and selective CDK inhibitor with IC₅₀s of 4.6 μM, 83 μM, and 2.7 μM for Cdk2/cyclin E, Cdk2/cyclin A, and Cdk9/cyclin T1, respectively. Bohemine also inhibits ERK2 with an IC₅₀ of 52 μM and has less inhibitory effect on CDK1, CDK4 and CDK6. Bohemine has a broad spectrum anti-cancer activities ^[1] .

HY-P10219

Brevicidine analog 22	Bacterial	Infection Inflammation/Immunology
Brevicidine analog 22 (22) exerts broad spectrum antimicrobial activity and excellent stability (t_1/2 = 40.98 h), with MICs of 2-16 μM for gram-negative and gram-positive bacteria ^[1].

HY-128900

11-cis-Vaccenyl acetate	Endogenous Metabolite	Others
11-cis-Vaccenyl acetate is male-specific lipid that mediates aggregation behavior in both male and female flies, which activates a few dozen olfactory neurons located in T1 sensilla on the antenna of both male and female flies ^[1].

HY-168515

CDK9-IN-35	CDK	Cancer
CDK9-IN-35 (compound 10j) is an inhibitor of CDK9/Cyclin T1 with an IC₅₀ value of 10.2 nM and against the HCT-116 cell line with an IC₅₀ value of 20 nM ^[1].

HY-160287

NVS MLLT-1	Epigenetic Reader Domain	Cancer
NVS MLLT-1 (compound 3) is a potent and selective *MLLT1* inhibitor with K_d values of 0.18 µM, 0.24 µM, and 0.22 µM for wild-type, T1 mutants, and T3 mutants, respectively ^[1] .

HY-153822

JG-23	Tau Protein	Neurological Disease
JG-23 is a 4-chloro modified analog with ability to promote t-tau degradation. JG-23 exhibits good metabolic stability with a long T1/2 value (36 min) in mouse liver microsome assays ^[1].

HY-113567

GSK2324	FXR	Metabolic Disease
GSK2324 (Compd 1c) is a FXR agonist for diabetes study, with an EC₅₀ of 120 nM. GSK2324 exhibits t_1/2 values of 84 min (mouse), 170 min (rat), 110 min (beagle) and 120 min (cyno), respectively ^[1].

HY-162655

SLF80821178	LPL Receptor	Neurological Disease
SLF80821178 is a potent and orally active inhibitor of Sphingosine-1-Phosphate Transporter (Spns2). SLF80821178 inhibits S1P release with an IC₅₀ of 51 nM in HeLa cells and a T_1/2 of 2.4 h in mouse ^[1].

HY-100866B

F1324 acetate	Bcl-2 Family	Cancer
F1324 acetate is a potent, high affinity peptidic inhibitor of B cell lymphoma 6 (BCL6), with an IC₅₀ of 1 nM. F1324 acetate exhibits binding t_1/2 value of 441 s and has strong inhibition activity against BCL6 PPI ^[1].

HY-N14776

11-Demethyltomaymycin	Antibiotic Bacterial	Infection Cancer
11-Demethyltomaymycin is an antibiotic. 11-Demethyltomaymycin has antiviral activity against Escherichia coli T₁ and T₃ phages and antibacterial activity against Gram-positive bacteria. In addition, 11-Demethyltomaymycin is cytotoxic to leukemia L1210 cells ^[1] .

HY-100866

F1324	Bcl-2 Family	Cancer
F1324 is a potent, high affinity peptidic inhibitor of B cell lymphoma 6 (BCL6) with an IC₅₀ of 1 nM. F1324 exhibits binding t_1/2 value of 441 s and has strong inhibition activity against BCL6 PPI ^[1].

HY-139721

Tenofovir-C3-O-C15-CF3 ammonium	HIV	Infection
Tenofovir-C3-O-C15-CF3 (ammonium) exhibits substantially longer t1/2 values than tenofovir in human liver microsomes, potent anti-HIV activity in vitro, and enhances pharmacokinetic properties in vivo.

HY-100866A

F1324 TFA	Bcl-2 Family	Cancer
F1324 TFA is a potent, high affinity peptidic inhibitor of B cell lymphoma 6 (BCL6), with an IC₅₀ of 1 nM. F1324 TFA exhibits binding t_1/2 value of 441 s and has strong inhibition activity against BCL6 PPI ^[1].

HY-N12728

Heteroclitin G	Others	Others
Heteroclitin G is a lignan which can be extracted from Dian-Jixueteng. Heteroclitin G (2.0 mg/kg, i.v.) exerts an C_5min of 665.97 ± 29.89 ng/mL and T_1/2z of 5.04 ± 1.84 h ^[1].

HY-162406

UNC8969	TAM Receptor	Cancer
UNC8969 (compound 43) is a MERTK/AXL dual inhibitor with IC₅₀s of 1.1±0.8 nM for MERTK and 5.3 ± 2.7 nM for AXL. UNC8969 also exerts a *T_1/2* of 7.3 h with 5 mg/kg i.v. in mice ^[1].

HY-100429

CAN508 1 Publications Verification	CDK	Cancer
CAN508 is a potent, ATP-competitive CDK9/cyclin T1 inhibitor with an IC₅₀ of 0.35 μM. CAN508 exhibits a 38-fold selectivity for CDK9/cyclin T over other CDK/cyclin complexes. Antitumor activity ^[1] .

HY-112624O

Dextran T100 (MW 100,000) Dextran 100; Dextran D100; Dextran T100(MW 90000-110000)	Biochemical Assay Reagents	Others
Dextran T200 MW 200,000 (Dextran D200; Dextran T200 MW 180000-220000) is a polymer of anhydroglucose with the average molecular weight of 1000. Dextran T1 MW 1,000 exhibits good biodegradability and good biocompatibility, that is utilized in food, pharmaceutics, cosmetics, and research area ^[1].

HY-159489

SDUY038	SHP2	Cancer
SDUY038 is a SHP2 allosteric inhibitor, with an IC₅₀ of 1.2 μM and K_D of 0.29 μM, respectively. SDUY038 exhibits pan-antitumor activity (IC₅₀ = 7-24 μM) by suppressing pERK expression. SDUY038 exhibits t_1/2 of 3.95 h by oral administration ^[1].

HY-119120

JTK-101	HIV CDK	Infection Inflammation/Immunology
JTK-101 is a selective HIV inhibitor. JTK-101 selectively reduces *HIV-1* mRNA synthesis by inhibiting Tat cofactors, including CDK9 and cyclin T1, thereby suppressing the transcriptional activity of HIV-1. JTK-101 may be used in the field of anti-HIV virus research ^[1].

HY-162409

PAR4 antagonist 4	Protease Activated Receptor (PAR)	Others
PAR4 antagonist 4 (Compound 37) is a selective antagonist for protease activated receptor 4 (PAR4). PAR4 antagonist 3 exhibits antiplatelet efficacy with IC₅₀ of 14.2 nM. PAR4 antagonist 3 improves metabolic stablility in human liver microsomes with T_1/2 of 42.5 min ^[1].

HY-128947

CL2 Linker	ADC Linker	Cancer
CL2 Linker is a cleavableADC linker. CL2-SN-38 and CL2A-SN-38 are equivalent in agent substitution (~6), cell binding (K_d ~1.2 nM), cytotoxicity (IC₅₀ ~2.2 nM), and serum stability in vitro (t_1/2 ~20 hours) ^[1] .

HY-146054

CXCR4 modulator-2	CXCR	Inflammation/Immunology
CXCR4 modulator-2 (compound Z7R) is a highly potent CXCR4 modulator with an IC₅₀ value of 1.25 nM. CXCR4 modulator-2 has acceptable stability (t_1/2 = 77.1 min) in mouse serum and exhibits anti-inflammatory activity in mouse edema model ^[1].

HY-162408

PAR4 antagonist 3	Protease Activated Receptor (PAR)	Others
PAR4 antagonist 3 (Compound 36) is a selective antagonist for protease activated receptor 4 (PAR4). PAR4 antagonist 3 exhibits antiplatelet efficacy with IC₅₀ of 26.1 nM. PAR4 antagonist 3 improves metabolic stablility in human liver microsomes with T_1/2 of 97.6 min ^[1].

HY-170911

KIT/PDGFRA-IN-1	PDGFR	Cancer
KIT/PDGFRA-IN-1 (compound 19) is a stem cell growth factor receptor (KIT) and platelet-derived growth factor receptor alpha (PDGFRA) inhibitor. KIT/PDGFRA-IN-1 inhibits KIT-wt, KIT-D816H, KIT-T670I, PDGFRA-wt, PDGFRA-D842V, PDGFRA-T674I and PDGFRA-G680R with IC₅₀s of 2.3, 12, 492, 0.8, 99.9, 42.3, and 4.3 μM, respectively. KIT/PDGFRA-IN-1 inhibits GIST-T1, T1-a-D842V and GIST-48B cells (PDGFR- and KIT-Mutant GIST cell Lines) with GR₅₀s of 12, 8900, ≥10 000 nM, respectively ^[1].

HY-149920

Anticancer agent 98	Microtubule/Tubulin	Cancer
Anticancer agent 98 (compound 12k) is a microtubule/tubulin-polymerization inhibitor (K_d=16.9 μM). Anticancer agent 98 exerts antiproliferative potency against tumor cells, exhibits anti-angiogenesis effect in vitro. Anticancer agent 98 exhibits good human and mouse liver microsomes stability with both t_1/2>300 min ^[1].

HY-158090

Triptolide palmitate	Others	Cancer
Triptolide palmitate is the derivative of Triptolide (HY-32735). Triptolide palmitate exhibits cytotoxicity against cancer cell MCF-7 and A549, with IC₅₀ of 7.5 and 6.4 μM. Triptolide palmitate exhibits a half-time T_1/2 of 50.4 min in Sprague Dawley rats. Triptolide palmitate can be utilizd as drug carrier ^[1].

HY-155354

Antimalarial agent 33	Parasite	Infection
Antimalarial agent 33 (compound 5g) has antiplasmodial activity against erythrocytic and hepatic stages of Plasmodium with an EC₅₀ of 1.1 μM for K1 P. falciparum strain. Antimalarial agent 33 demonstrats enhanced microsomal stability (T_1/2=29 min). Antimalarial agent 33 has no significant cytotoxicity against primary hepatocytes ^[1].

HY-118717

mTOR inhibitor WYE-28	mTOR	Cancer
mTOR inhibitor WYE-28 (compound 28) is a selective inhibitor of mTOR>/b< (IC₅₀)=0.08 nM. mTOR inhibitor WYE-28 inhibits PI3Kα** with an IC50 value of 6 nM. mTOR inhibitor WYE-28 shows a metabolic time (T_1/2) in nude mouse microsomes of 13 min ^[1].**

HY-168930

ATX inhibitor 25	Phosphodiesterase (PDE)	Inflammation/Immunology
ATX inhibitor 25 (Compound 29) is an orally active Autotaxin inhibitor with an IC₅₀ of 1.08 nM. ATX inhibitor 25 exhibits excellent in vitro metabolic stability, with a *t_1/2* of more than 170 minutes. In the bleomycin (HY-108345)-induced pulmonary fibrosis mouse model, orally administered ATX inhibitor 25 shows anti-fibrotic effects ^[1].

HY-155065

SB-1295	Reactive Oxygen Species Apoptosis CDK	Cancer
SB-1295 is an orally active *CDK9/T1* inhibitor (IC₅₀=0.17 μM). SB-1295 shows antiproliferative activity in HCT 116 and MIA PaCa-2 cells. SB-1295 also induces MIA PaCa-2 cell death by inducing intracellular ROS production, reducing mitochondrial membrane potential and inducing apoptosis. SB-1295 has the potential to study cancer ^[1].

HY-144731

gp120-IN-2	HIV	Inflammation/Immunology
gp120-IN-2 (compound 4i) is a potent HIV-1 gp120 inhibitor with an IC₅₀ of 7.5 µM and CC₅₀ of 112.93 µM. gp120-IN-2 shows anti-HIV-1 activity. gp120-IN-2 shows cytotoxicity in a dose dependent manner in SUP-T1 cells ^[1].

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-128900

11-cis-Vaccenyl acetate	Structural Classification Natural Products Classification of Application Fields Source classification Other Diseases Endogenous metabolite Disease Research Fields	Endogenous Metabolite
11-cis-Vaccenyl acetate is male-specific lipid that mediates aggregation behavior in both male and female flies, which activates a few dozen olfactory neurons located in T1 sensilla on the antenna of both male and female flies ^[1].

HY-N2541

Gymnemic acid I	Triterpenes Structural Classification Classification of Application Fields Terpenoids Source classification Asclepiadaceae Metabolic Disease Plants Disease Research Fields Gymnema sylvestre (Retz.) Schult.	Taste Receptor mTOR Autophagy Apoptosis
Gymnemic acid I is a bioactive triterpene saponin found in Gymnema sylvestre. Gymnemic acid I is an antisweetness inhibitor via human sweet receptor type 1 receptor 2 (T1R2) and *T1R3. Gymnemic acid I is a ribosomal protein biosynthesis inhibitor. Gymnemic acid I has antidiabetic effects. Gymnema acid I induces autophagy-protected MIN-6 cells from apoptosis* under high glucose stress by inhibiting the phosphorylation activity of mTOR ^[1] .

HY-108568

15-Deoxy-Δ-12,14-prostaglandin J2 1 Publications Verification 15d-PGJ2; 15-Deoxy-Δ12,14-PGJ2	Structural Classification Neurological Disease Classification of Application Fields Ketones, Aldehydes, Acids Source classification Endogenous metabolite Inflammation/Immunology Disease Research Fields	PPAR Endogenous Metabolite
15-Deoxy-Δ-12,14-prostaglandin J2 (15d-PGJ2) is a cyclopentenone prostaglandin and a metabolite of PGD2. 15-Deoxy-Δ-12,14-prostaglandin J2 is a selective PPARγ (EC₅₀ of 2 µM) and a covalent PPARδ agonist. 15-Deoxy-Δ-12,14-prostaglandin J2 promotes efficient differentiation of C3H10T1/2 fibroblasts to adipocytes with an EC₅₀ of 7 μM ^[1] .

HY-N11648

Ganoderic acid T1	Triterpenes Structural Classification Microorganisms Terpenoids Source classification	Apoptosis Caspase
Ganoderic acid T1 is a deacetylated derivative of Ganoderic acid T. Ganoderic acid T1 attenuates antioxidant defense system and induces apoptosis of cancer cells. Ganoderic acid T1 decreases mitochondrial membrane potential and activates caspase-9 and caspase-3, to trigger apoptosis. Ganoderic acid T1 also increases the generation of intracellular ROS to produce pro-oxidant activities and cytotoxicity ^[1].

HY-N14436

Pradimicin Tl	Structural Classification Microorganisms Antibiotics Source classification Other Antibiotics	Antibiotic Fungal
Pradimicin T1 is an antibiotic. Pradimicin Tl has activity against filamentous fungi and yeast-like fungi ^[1].

HY-N14776

11-Demethyltomaymycin	Structural Classification Natural Products Microorganisms Source classification	Antibiotic Bacterial
11-Demethyltomaymycin is an antibiotic. 11-Demethyltomaymycin has antiviral activity against Escherichia coli T₁ and T₃ phages and antibacterial activity against Gram-positive bacteria. In addition, 11-Demethyltomaymycin is cytotoxic to leukemia L1210 cells ^[1] .

HY-N12728

Heteroclitin G	Structural Classification Kadsura heteroclita (Roxb.) Craib Source classification Lignans Phenylpropanoids Plants Schisandraceae	Others
Heteroclitin G is a lignan which can be extracted from Dian-Jixueteng. Heteroclitin G (2.0 mg/kg, i.v.) exerts an C_5min of 665.97 ± 29.89 ng/mL and T_1/2z of 5.04 ± 1.84 h ^[1].

HY-N6720

T-2 Triol	Microorganisms Classification of Application Fields Terpenoids Sesquiterpenes Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Endogenous Metabolite
T-2 Triol is a trichothecene mycotoxin derived by the metabolism of T-2 toxin. It is less toxic than T-2 toxin ^[1]. T-2 Triol major metabolites are evaluated in broiler chickens with Half-lives (t_1/2λz), Peak plasma concentrations (C_max) and T_max values of 9.6 mins, 563 ng/ml , 2.5 mins, respectively .

HY-108568R

15-Deoxy-Δ-12,14-prostaglandin J2 (Standard)	Structural Classification Ketones, Aldehydes, Acids Source classification Endogenous metabolite	PPAR Endogenous Metabolite
15-Deoxy-Δ-12,14-prostaglandin J2 (Standard) is the analytical standard of 15-Deoxy-Δ-12,14-prostaglandin J2. This product is intended for research and analytical applications. 15-Deoxy-Δ-12,14-prostaglandin J2 (15d-PGJ2) is a cyclopentenone prostaglandin and a metabolite of PGD2. 15-Deoxy-Δ-12,14-prostaglandin J2 is a selective PPARγ (EC₅₀ of 2 μM) and a covalent PPARδ agonist. 15-Deoxy-Δ-12,14-prostaglandin J2 promotes efficient differentiation of C3H10T1/2 fibroblasts to adipocytes with an EC₅₀ of 7 μM ^[1] .

Cat. No.	Product Name	Chemical Structure

HY-108568S

15-Deoxy-Δ-12,14-prostaglandin J2-d4

15-Deoxy-Δ-12,14-prostaglandin J2-d₄ is the deuterium labeled 15-Deoxy-Δ-12,14-prostaglandin J2. 15-Deoxy-Δ-12,14-prostaglandin J2 (15d-PGJ2) is a cyclopentenone prostaglandin and a metabolite of PGD2. 15-Deoxy-Δ-12,14-prostaglandin J2 is a selective PPARγ (EC50 of 2 µM) and a covalent PPARδ agonist. 15-Deoxy-Δ-12,14-prostaglandin J2 promotes efficient differentiation of C3H10T1/2 fibroblasts to adipocytes with an EC50 of 7 μM[1][2].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks